OpGen > Investor Relations > Overview


Corporate Profile

OpGen, Inc. is an early commercial stage company using molecular testing and bioinformatics to assist healthcare providers to combat multi-drug resistant bacterial infections. The company’s products and services are designed to enable the rapid identification of hospital patients who are colonized or infected with life-threatening, multi-drug resistant organisms, or MDROs. The company’s lead product is the Acuitas® MDRO Gene Test. Products in development include the Acuitas Lighthouse™ MDRO Management System and the Acuitas Resistome Test. In addition, the company has more than 10 years of experience mapping microbial, plant and human genomes.

Upcoming Events

World Anti-Microbial Resistance Congress 2016
Thursday, September 8, 2016 through Friday, September 9, 2016
Rodman & Renshaw 18th Annual Global Investment Conference
Sunday, September 11, 2016 through Tuesday, September 13, 2016
Anti-Infectives Rx
Wednesday, September 21, 2016

More Events

OPGN (Common Stock)
Exchange :NASDAQ CM (US Dollar)
Financial Status IndicatorC
Price :$1.73
Change : Stock is Down 0.1 (5.46%)
Volume :29,264
Data as of 08/23/16 4:00 p.m. ET
Minimum 20 minute delay
Data Provided by Thomson Reuters